Sarepta Therapeutics Statistics

Total Valuation

LON:0L35 has a market cap or net worth of GBP 1.41 billion. The enterprise value is 2.03 billion.

Market Cap	1.41B
Enterprise Value	2.03B

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	98.28M
Shares Outstanding	n/a
Shares Change (YoY)	+0.83%
Shares Change (QoQ)	-10.24%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	6.96
PS Ratio	0.81
PB Ratio	1.59
P/TBV Ratio	1.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 79.60, with an EV/FCF ratio of -3.76.

EV / Earnings	-10.54
EV / Sales	1.22
EV / EBITDA	79.60
EV / EBIT	n/a
EV / FCF	-3.76

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.19.

Current Ratio	4.02
Quick Ratio	2.06
Debt / Equity	1.19
Debt / EBITDA	39.65
Debt / FCF	-1.95
Interest Coverage	-6.26

Financial Efficiency

Return on equity (ROE) is -23.61% and return on invested capital (ROIC) is -3.02%.

Return on Equity (ROE)	-23.61%
Return on Assets (ROA)	-2.19%
Return on Invested Capital (ROIC)	-3.02%
Return on Capital Employed (ROCE)	-4.10%
Revenue Per Employee	1.26M
Profits Per Employee	-140,124
Employee Count	1,372
Asset Turnover	0.67
Inventory Turnover	2.71

Taxes

In the past 12 months, LON:0L35 has paid 65.17 million in taxes.

Income Tax	65.17M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.95% in the last 52 weeks. The beta is 0.60, so LON:0L35's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	-87.95%
50-Day Moving Average	31.66
200-Day Moving Average	87.94
Relative Strength Index (RSI)	30.92
Average Volume (20 Days)	38,501

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.72

Income Statement

In the last 12 months, LON:0L35 had revenue of GBP 1.73 billion and -192.25 million in losses. Loss per share was -2.00.

Revenue	1.73B
Gross Profit	348.06M
Operating Income	-90.72M
Pretax Income	-127.08M
Net Income	-192.25M
EBITDA	-60.57M
EBIT	-90.72M
Loss Per Share	-2.00

Full Income Statement

Balance Sheet

The company has 404.61 million in cash and 1.05 billion in debt, giving a net cash position of -645.48 million.

Cash & Cash Equivalents	404.61M
Total Debt	1.05B
Net Cash	-645.48M
Net Cash Per Share	n/a
Equity (Book Value)	884.46M
Book Value Per Share	9.00
Working Capital	1.41B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -423.49 million and capital expenditures -114.68 million, giving a free cash flow of -538.16 million.

Operating Cash Flow	-423.49M
Capital Expenditures	-114.68M
Free Cash Flow	-538.16M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 20.14%, with operating and profit margins of -5.25% and -11.12%.

Gross Margin	20.14%
Operating Margin	-5.25%
Pretax Margin	-7.35%
Profit Margin	-11.12%
EBITDA Margin	-3.50%
EBIT Margin	-5.25%
FCF Margin	n/a

Dividends & Yields

LON:0L35 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.83%
Shareholder Yield	n/a
Earnings Yield	-13.68%
FCF Yield	-38.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0L35 has an Altman Z-Score of 2.33 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.33
Piotroski F-Score	1